MGUS

Dr. S. Vincent Rajkumar, from the Division of Hematology at Mayo Clinic, discusses advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance and implications for recategorizing disease entities, which will be published in the October 2010 issue of Mayo Clinic Proceedings (Available at: http://tinyurl.com/39g8n6x).

Dr. Shaji K Kumar, Associate Professor of Hematology and Medicine at Mayo Clinic in Rochester, MN, discusses updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines (direct link available at http://tiny.cc/V2dk9 or visit journal at www.mayoclinicproceedings.com). The identification of well-defined and reproducible prognostic factors and introduction of new therapies with unique modes of action and impact on disease outcome have for the first time opened...

Dr. S. Vincent Rajkumar, Mayo Clinic hematologist, discusses the first systematic study (published in August issue of Mayo Clinic Proceedings available at http://tinyurl.com/lr55lc) to determine association of Monoclonal Gammopathy of Undetermined Significance (MGUS) with all diseases in 17,398 patients.